Epidural Analgesia Versus IV Meperidine for Labor Pain Control

Not Applicable

Completed

• Conditions: Labor Pain

• Registration Number: NCT00296751
• Lead Sponsor: Rambam Health Care Campus

Brief Summary

60 female that care for pain control during second stage of delivery, will choose between epidural or systemic analgesia. Continuous ECG (3 lead)monitoring will be recorded during the second stage for 10 minutes. 30 minutes after administration of either pain relief, a second recording of maternal ECG will take place for 10 minutes.

Detailed Description

Population 60 female during second stage of delivery

* Inclusion criteria : all parturients requiring pain relief will choose between systemic or epidural analgesia.

* Exclusion Criteria: all parturients with cardiac disease, neurological disease, endocrine disease, diabetes, hypertension or any parturients being treated with medications that might effect the cardiovascular autonomic system.

* Method: A 10 minute recording of a 3 lead ECG will be performed during the second stage of the delivery (3-7 CM opening).

the parturient will be lying on her left side for that period.

* 30 minutes after administration of either epidural or systemic Meperidine for pain relief, a second recording of maternal ECG will take place for 10 minutes.

* estimated duration of the procedure about one hour per woman.

Study Timeline

• Study First Submitted: 2006-02-24
• Study First Submitted QC: 2006-02-24
• Study First Posted: 2006-02-27
• Study Start: 2006-03
• Primary Completion: 2006-12
• Study Completion: 2006-12
• Status Verified: 2008-04
• Last Update Submitted: 2010-06-30
• Last Update Posted: 2010-07-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

all parturients requiring pain relief will choose between systemic or epidural analgesia.

Exclusion Criteria

all parturients with cardiac disease, neurological disease, endocrine disease, diabetes, hypertension or any parturients being treated with medications that might effect the cardiovascular or autonomic system.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Three lead ECG monitoring for 10 minutes will be performed 30 minutes after the administration.

Trial Locations

Locations (1)

Rambam - health care campus; 🇮🇱 Haifa, Israel